# US 9,872,841 B2 · Application of R-ketamine and salt thereof as pharmaceuticals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,841 B2
- Document ID: US9872841B2
- Status: Granted
- Kind: B2
- Application number: 15/021,003
- Filed: 2014-09-12
- Published: 2016-08-04
- Granted: 2018-01-23
- Earliest claimed: 2013-09-13
- Assignees: National University Corporation Chiba University
- Applicants: National University Corporation Chiba University
- Inventors: Kenji Hashimoto
- Web page: https://patentgrep.com/patent/US9872841B2

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

## Claims

### Claim 1

A method of treating a depressive symptom, comprising administering R(−)-ketamine or a pharmacologically acceptable salt thereof to a subject, wherein the subject has been diagnosed with having a depressive symptom, in an amount effective to treat the depressive symptom, and being substantially free of S(+)-ketamine or a pharmacologically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the subject has been diagnosed with depression in children or adults.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the subject has been diagnosed with obsessive-compulsive disorder.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the subject has been diagnosed with posttraumatic stress disorder.

### Claim 5

A method of treating a depressive symptom, comprising administering a pharmaceutical composition to a subject, wherein the pharmaceutical composition comprises R(−)-ketamine or a pharmaceutically acceptable salt thereof in an amount effective to treat a depressive symptom, and a pharmaceutically acceptable carrier, and being substantially free of S(+)-ketamine or a pharmacologically acceptable salt thereof, and wherein the subject has been diagnosed with having a depressive symptom.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the subject has been diagnosed with depression in children or adults.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the subject has been diagnosed with obsessive-compulsive disorder.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the subject has been diagnosed with posttraumatic stress disorder.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition being substantially free of S(+)-ketamine contains no S(+)-ketamine or a pharmacologically acceptable salt thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition being substantially free of S(±)-ketamine contains S(+)-ketamine or a pharmacologically acceptable salt thereof in such an amount that its side effects are not exhibited.